Alnylam Pharmaceuticals Inc (MEX:ALNY)
MXN 2453 0 (0%) Market Cap: 323.08 Bil Enterprise Value: 304.86 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 68/100

Alnylam Pharmaceuticals Inc at Stifel CNS Days (Virtual) Transcript

Mar 28, 2022 / 06:00PM GMT
Release Date Price: MXN2911.32
Paul Andrew Matteis
Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst

Great. Thanks very much. It's my pleasure to be moderating this panel with Kevin Fitzgerald, Alnylam's Chief Scientific Officer. And on this panel, we're going to specifically talk about Alnylam's efforts in neuroscience as you guys are expecting some proof of principle, proof of concept data by the end of this year.

Questions & Answers

Paul Andrew Matteis
Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst

So maybe, Kevin, to kind of kick it off, right? I think most folks know about the history of GalNAc in the liver, what did you need to achieve to be able to safely deliver RNAi therapeutics that can penetrate and engage the target in different areas of the brand?

Kevin Joseph Fitzgerald
Alnylam Pharmaceuticals, Inc. - Senior VP, Head of Research & Chief Scientific Officer

Yes. So thank you for

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot